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The Conference on Retroviruses and
Opportunistic Infections (CROI), despite its
awkward and outmoded name, has become
the most important venue for the dissemina-
tion of results from HIV-related research in the
U.S. and, arguably, the world.  The 10th CROI
held in Boston on February 10-14 was more
clinically oriented than most of the preceding
conferences and saw results from several
important clinical trials presented, as well as
preliminary data from studies of new antiretro-
viral agents and updates on the epidemiology
of the epidemic.
Clinical Trial Results
2NN Study
A presentation of the large Boehringer
Ingleheim-sponsored 2NN Study1 by
International AIDS Society President Joep
Lange was of key interest to many attending
the conference. These long-awaited results
detailed the efficacy and safety of initial anti-
retroviral therapy with stavudine (d4T) and
lamivudine (3TC), plus one of the following: 
w nevirapine (NVP) 400 mg QD, 
w NVP 200 mg BID,
w efavirenz (EFV) 600 QD, or 
w a combination of NVP 400 mg QD + 
EFV 800 mg QD
A total of 1,216 subjects enrolled in 17 coun-
tries. All subjects were treatment naïve; medi-
an HIV viral load and CD4+ cell count were 4.7
log10 copies/mL (~50,000 copies/mL) and
109/uL, respectively. Treatment failure was
defined as less than a 1 log10 decline in HIV
RNA level by week 12, two consecutive viral
load measurements above 50 copies/mL after
week 24, a new Centers for Disease Control
and Prevention (CDC) category C diagnosis or
death, or change of study-assigned therapy. 
About 84% of subjects completed the study.
After 48 weeks, success (absence of above-
defined failure) was fairly comparable across
arms with 56% of the NVP QD arm, 56% of the
NVP BID arm, 62% of the EFV arm and 47%
of the NVP+EFV arm achieving this endpoint.
A statistically significant difference was only
seen between the EFV and the NVP+EFV
rms. A change in treatment occurred most
commonly in the dual Non-Nucleoside
Reverse Transcriptase Inhibitor (NNRTI)
assigned subjects (34.5%), followed by NVP
QD (29%) and less commonly NVP BID (22%)
and EFV (20%). In an intent to treat analysis,
the proportion of subjects with a viral load
below 50 copies/mL at week 48 was 70% in
both the NVP QD and the EFV arms, 65% in
the NVP BID arm and 63% in the dual NNRTI
arm. Response to treatment based on base-
line viral load demonstrated a decline in treat-
ment success rates in all the study arms when
the HIV RNA level was >100,000 copies/mL at
entry with a suggestion that the EFV arm tend-
ed to be superior compared to the NVP arms.
CD4+ cell counts increased in all the groups
not dissimilarly with approximately a 140-150
cell/uL rise experienced from baseline to week
48. 
While virologic and immunologic efficacy was
not wildly different among arms, adverse
events did distinguish the study regimens.
Overall, there was more toxicity reported in the
NVP containing arms than the EFV arm. The
proportion of subjects who had treatment limit-
ing adverse events in the four arms ranged
from 30% in the dual NNRTI arm to 15.5% in
the EFV QD arm; 24% of the NVP QD and
21% of the NVP BID discontinued therapy dur-
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ing the study. Hepatotoxicity comprised
the lion's share of grade 3 (severe) and
grade 4 (life threatening) laboratory toxic-
ity with 13.2% of the NVP QD, 7.8% of the
NVP BID, 4.5% of the EFV QD and 8.6%
of the dual NNRTI subjects experiencing
elevations of ALT and/or AST (p<0.001
NVP QD vs. EFV QD). About 10% of the
cohort was HCV seropositive and 5% had
active HBV infection and these patients
were distributed equally across the study
arms. CNS adverse events were not sur-
prisingly significantly higher among those
taking EFV (5.5% had grade 3 or 4 CNS
toxicity in this arm). 
During the trial, 25 people died. Eleven of
these deaths were associated with HIV
disease and another 11 from non-HIV or
study treatment related causes (including
a number of murders occurring in South
Africa). In the remaining three cases,
death was attributed to study medication:
one died from lactic acidosis associated
with d4T use, one woman developed fatal
toxic hepatitis while on NVP without evi-
dence of viral hepatitis and another man
also receiving NVP developed Stevens-
Johnson Syndrome and subsequent ful-
minate sepsis. 
This long-awaited study demonstrated
parity in potency between NVP and EFV
and the feasibility of once daily dosing
with NVP. The higher rates of serious tox-
icity, specifically hepatotoxicity, in the NVP
arms may dampen some clinicians' enthu-
siasm for once a day NVP, although oth-
ers may opt for this convenient alternative
to EFV coupled with close monitoring of
liver functions.
903 Study
Another study with implications for clinical
care, the Gilead 903 Study2, pitted teno-
fovir (TDF) against d4T as part of a three-
drug regimen with 3TC and EFV in 600
antiretroviral naïve patients. In a presen-
tation of 96-week results from this trial, the
extremely high rates of viral suppression
reported after 48 weeks have persisted. In
both study arms the proportion of subjects
with a viral load less than 50 copies/mL
was between 74% and 78% - a response
that is all the more impressive considering
the median baseline viral load was 81,000
copies/mL and the median entry CD4+
cell count 276/mm3. 
However, as in the 2NN Study, it is the
toxicities that set the regimens apart.
Fasting triglyceride levels rose significant-
ly higher in the d4T+3TC+EFV arm com-
pared to those assigned to
TDF+3TC+EFV (100 mg/dL vs. 5 mg/dL,
p=0.001). Likewise, total cholesterol
increased 50 mg/dL in the d4T group and
30 mg/dL in the TDF group. Reflecting
these changes in lipids and indicating
their clinical significance, rates of new
statin and fibrate use during the study was
much higher in the d4T subjects than the
TDF patients (10% vs. 2%). Other meta-
bolic complications were also compared.
Investigator-defined lipodystrophy was
reported in four times as many d4T sub-
j cts. Differences between limb fat at 96
weeks by DEXA scanning were also seen.
Those assigned TDF had about eight
pounds more peripheral fat than d4T sub-
jects. DEXAs were also obtained longitu-
dinally to assess bone density. These
results were released after the conference
and demonstrated slight declines in bone
mineralization in both study arms.
However, although the differences
between arms were statistically signifi-
cant, thus far, they are of limited clinical
significance.  
This important study indicates that teno-
fovir can hold its own against d4T in sup-
pressing viral replication and does so with
less toxicity. That the study compared two
regimens that can both now be adminis-
tered once daily was prescient - and cer-
tainly increases the attractiveness of the
TDF regimen within corrections. 
egylated Interferon for Early-Stage
HIV
Researchers from Germany presented
r sults of a study3 that treated early-stage
HIV-positive patients with weekly injec-
tions of pegylated interferon Alfa-2b
(PegIntron). Ten patients with early-stage
HIV and no symptoms who had not yet
received treatment were studied; five
patients received weekly PegIntron injec-
tions while the other five patients received
no treatment. 
At baseline the average CD4 count in the
group that received therapy was 462; the
control group CD4 count averaged 535.
After six months, the average CD4 count
in the treatment group had increased to
611 while the average CD4 in the control
roup dropped to 450. Viral load in the
group receiving therapy dropped from
22,158 copies/mL to 3,039 copies/mL.
The viral load in the control group went
from 7,136 copies/mL to 40,092
copies/mL.
The presenters reported no serious side
effects in the treatment group, perhaps
due to the fact that the PegIntron dose
was half the standard dose used for
hepatitis C therapy.
This study of a small number of patients
offers some intriguing data on the favor-
able immunologic and virologic effects of
interferon therapy. Further studies are
needed to assess the longer-term effects
and toxicities when using interferon to
treat patients with early-stage HIV infec-
tion.
Drug-Drug Interactions
Tenofovir and ddI
In addition to results of large clinical trials,
several reports focused on important drug
interactions of the agents currently used
to treat HIV infection. As many providers
know, co-administration of tenofovir and
didanosine (ddI) leads to elevated plasma
levels of ddI and, therefore, potential
heightened risk of ddI-related toxicity. In
contrast, ddI does not alter tenofovir lev-
e s. In response to the effect of tenofovir
on ddI levels, clinicians have been using a
reduced dose of 250 mg of ddI-EC
(enteric coated) along with tenofovir. 
The pharmacokinetics of this dose of ddI-
EC when coupled with tenofovir in a fed
and fasted state was studied4 in HIV-unin-
fected volunteers. Dosing of 250 mg ddI-
EC on an empty stomach followed two
hours later by 300 mg tenofovir and a light
meal resulted in a ddI exposure identical
to that seen when ddI-EC is administered
as 400 mg by itself. Concomitant adminis-
tration of 250 mg ddI-EC and tenofovir
without food led to a slightly lower ddI
exposure relative to 400 mg of ddI-EC
(88.6% geometric mean exposure) but
when the two were taken with food, ddI
levels increased by 114%. Generally,
these data indicate that a dose reduction
of enteric-coated ddI to 250 mg is appro-
priate when this agent is used with teno-
fovir however, it should be noted that all
subjects weighed over 60 kg. The differ-
nces in exposure in the various scenar-
ios tested were not major and the conve-
nience of being able to take both medica-
ions with a light meal has led many to rec-
mmend this dosing schedule to their
patients. Appropriate dosing in those who
weigh less than 60 kg is unclear and cer-
tainly requires further study.
Lopinavir/ritonavir and Phenytoin
Kashuba and colleagues examined a
potential drug-drug interaction between
lopinavir/ritonavir and the anticonvulsant
phenytoin (Dilantin)5. Lopinavir/ritonavir is
2
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Dear Correctional Colleagues:
This issue of HEPP focuses on the 10th annual Conference on Retroviruses and Opportunistic
Infections (CROI) held February 10-14 in Boston. The meeting opened with a well thought-out
and charismatic speech on HIV, politics, and citizenship in the world by former President Bill
Clinton. Clinton's accurate quotations of HIV statistics and grasp of the world AIDS problem
was mind-boggling and inspiring. Clinton spoke of work that his own foundation is doing
throughout the world to fight AIDS. He also praised President George W. Bush for pledging
$15 billion dollars to help fight AIDS in the highest prevalence countries. Clinton did caution
that systems need to be in place to ensure that countries that receive funding are prepared to
spend it effectively. 
Since its beginning, the organizers of CROI have focused on providing a forum for scientists
and clinicians to present, discuss, and critique presentations in the field of human retrovirolo-
gy and opportunistic infections. The number of attendees (3,200 this year) has always bee
limited; most are HIV researchers and clinicians. The paucity of pharmaceutical sales repre-
sentation is intentional. I, and many others, feel that CROI's restrictions are refreshing and help
keep the meeting more focused. Others feel that limiting who can attend CROI is elitism by the
medical and research communities at its their worst. One of my friends, a long-time AIDS
activist, told me recently that while he originally had adamantly protested the strict attendance
rules of CROI, he has come to understand them. 
In the current issue of HEPP, Drs. Wohl and Piliero summarize several important studies pre-
sented at CROI. I attended CROI and afterward, many colleagues told me that they didn't hear
much come out of this year's meeting. I was asked several times what I thought the most
important study was this year. Arguably, I believe the 2NN Study presented by Joep Lange
(and reviewed by Dr. Wohl in this issue of HEPP) receives that distinction. The 2NN Study pro-
vides further evidence that efavirenz is not more potent than nevirapine leaving us with two
powerful NNRTI options - each with their own set of positive and negative aspects. 
After reading this month's issue, you should be familiar with some of the data presented dur-
ing the 10th annual Conference on Retroviruses and Opportunistic Infections, including the
2NN Study, the 903 Study, the D:A:D Study, and several new antiretroviral therapies, among
others.
Stephen Tabet, M.D., MPH
University of Washington
Letter from the Editor
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an inhibitor of CYP3A4 and, like phenytoin,
a CYP450 inducer. Phenytoin is a sub-
strate for CYP2C9 and CYP2C19. To
investigate the interactions between these
agents, 24 HIV-uninfected volunteers were
randomized to two groups, the first of which
received lopinavir/ritonavir 400 mg BID for
10 days followed by concomitant adminis-
tration of the PI with 300 mg QD of pheny-
toin for 12 more days. The other arm start-
ed the study taking phenytoin alone and
then added lopinavir/ritonavir at day 11
through day 22.  Intensive pharmacokinet-
ics were performed and revealed a two-
way interaction between these drugs in
which levels of both are decreased.
Clinically, this may mean that phenytoin
levels may drop if lopinavir/ritonavir is
added; therefore levels of the anticonvul-
sant should be checked soon after the PI is
added. Levels of lopinavir may also drop
despite the low dose ritonavir present in the
formulation. Whether this reduced expo-
sure can be compensated for by the addi-
tion of more lopinavir/ritonavir is unclear as
this could lead to even greater reduction in
phenytoin.  Follow-up studies of the com-
plex interactions between these drugs and
possible regimen adjustments to compen-
sate are planned.
The interactions between phenytoin and
lopinavir/ritonavir are complex enough that
they should be not be co-administered in
the same patient.
Metabolic Complications
The centerpiece of the session on metabol-
ic complications associated with HIV was
the D:A:D Study6, a large meta-cohort
study of cardiovascular disease involving
23,468 subjects from the U.S., Europe and
Australia.  At baseline, participants had a
median age of 39 years, 24% were women,
55% had viral loads below the limits of
assay detection, 67% were PI experienced,
34% NNRTI experienced, 20-30% had ele-
vated total cholesterol or triglycerides and
60% were current smokers. During the
study, 126 subjects had probable or definite
myocardial infarctions (MIs), 28% of which
were fatal. Men experienced all but 10% of
the MIs. In an analysis of exposure to high-
ly active antiretroviral therapy (combination
treatment which includes a PI and/or an
NNRTI plus NRTIs) and outcome of MI,
there was a linear trend of increased risk of
MI with greater exposure to HAART. The
relative risk of MI increased by 1.26 (95%
CI, 1.12-1.41) per year of HAART exposure
(i.e. a 26% increased annual risk of MI).
Other factors that placed participants at risk
for MI included increased age, male gen-
der, previous cardiovascular disease,
smoking and elevated total cholesterol.
Enigmatically, the presence of clinician-
defined lipodystrophy was associated with
a decrease in MI risk. 
This important study is one of the first well-
designed studies to demonstrate an
increased risk of cardiovascular disease
among persons treated with HIV therapies.
Despite this risk, it remains important to
note that the overall life-sustaining benefits
of combination HIV treatment vastly out-
weigh the risks of therapy defined in this
study. Measures to reduce other cardiovas-
cular disease risk factors such as smoking
and treatment of dyslipidemia in antiretrovi-
ral treated patients can tilt the balance
even further in favor of HIV therapy.
Epidemiology
New data from the CDC presented in
Boston7 indicate that the number of AIDS
cases nationwide has increased for the first
time in several years. In addition, the num-
ber of new HIV infections in 25 reporting
states increased by 8% from 1999 to 2001.
The greatest increases in new HIV diag-
noses were seen in both men who have
sex with men and heterosexuals. These
are disturbing data and suggest that HIV
prevention measures are falling far short of
the mark. 
Further exacerbating the spread of the epi-
demic is the failure to identify a significant
proportion of persons with living with HIV
infection. It is estimated that as many as a
quarter of all HIV-infected persons in the
U.S. do not know that they are HIV positive.
Enhanced HIV testing in clinics and correc-
tional facilities can allow for the diagnosis,
counseling and treatment of persons who
are infected. In addition, interventions
aimed at transmission risk reduction can be
most effective when applied to those who
are aware of their HIV serostatus.
Appropriate diagnosis and treatment of
infected individuals can reduce viral burden
i  the blood and genital secretions, likely
reducing transmissibility. 
Conclusion
At a time where every several weeks it
seems there is another "major" HIV-related
conference, when there are dedicated
meetings for everything from antiretroviral
resistance to metabolic complications to
treatment adherence, the 10th CROI
proved to be impressively comprehensive.
There were few data specific to the conflu-
ence of HIV and corrections, but informa-
tion regarding strategies to optimize treat-
ment success and reduce drug toxicity, and
tr nds in the epidemiology of the epidemic
will serve physicians who treat HIV-infected
patients in jails and prisons well. While no
major breakthroughs were reported and the
ews was not always good, the data pre-
sented clearly inched our understanding of
HIV and its management forward - and, of
course, there is always next year. 
*Disclosures: Speaker's Bureau:
GlaxoSmithKline, Gilead, Merck, Roche, and
Abbott. Grant support from Roche.
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CROI: New Antiretroviral Agents
In addition to providing data on new antiretroviral agents in exist-
ing classes, the 10th Conference on Retroviruses and
Opportunistic Infections (CROI) also featured information on novel
therapeutic agents. All but one approved drugs for treating HIV
currently target one of two viral enzymes (reverse transcriptase
and protease); data was presented on new classes of agents that
target other viral processes as well.
New Therapeutic Classes
The first new class to arrive since 1996 is the fusion inhibitor class.
Data presented on enfuvirtide (Fuzeon), formerly known as T-20,
showed that the drug is well tolerated with the main exception
being injection site reactions due to a local reaction to the drug.
However, it was also shown that like the other classes of antiretro-
virals (ARVs), resistance to enfuvirtide can
develop, so it should be used with other
active ARV agents. Fuzeon was granted
FDA approval on March 13; see Inside News
(page 7). 
Data on the second-generation fusion
inhibitor, T-1249, were also presented. When
given to 25 patients who failed enfuvirtide,
they experienced a significant reduction in
viral load. This suggests that T-1249 could
be used to rescue enfuvirtide-resistant
strains of HIV. Phase 2 studies will begin
later this year. Enfuvirtide is expected to be
approved by the FDA within the month.
Another novel class of agents known as
CCR5 antagonists was presented. CCR5
antagonists block the binding of HIV to the CCR5 receptor on the
surface of the T lymphocyte, thereby blocking entry of HIV. In vitro
data on three compounds - AK602, TAK-220, and UK-427,857 -
were presented. Unlike fusion inhibitors that are given as a subcu-
taneous injection, these agents will be given orally. All appeared to
be potent inhibitors of CCR5 and should be entering Phase 1 trials
this year. 
Finally, data on approximately 24 HIV-positive patients given a sin-
gle IV infusion of TNX-355 were presented. This agent is an anti-
CD4 antibody that works by blocking the interaction of HIV with the
CD4 receptor on T cells by coating the receptor. Significant viral
load reductions were seen as far as 21 days after a single infusion.
This promising data support further studies using multiple doses.
Existing Therapy Classes
In the existing class category, we heard about a new Non-
Nucleoside Reverse Transcriptase Inhibitor (NNRTI) and two new
PI (Protease Inhibitor) candidates that have the potential to over-
come preexisting resistance. The data on the GlaxoSmithKline
NNRTI and the Roche PI were fromin vitrostudies, but the Tibotec
TMC-114 PI given to 50 patients with multi-PI-resistant HIV pro-
duced a significant decline in viral load in the first two weeks of
therapy.
There were data presented on atazanavir, which is expected to be
approved by the FDA this year. This once-a-day PI has been found
t  be kinder and gentler to lipids than its classmates. In a continu-
ation of a previously-reported study comparing two doses of
at zanavir combined with stavudine (d4T) + lamivudine (3TC) ver-
sus a combination of the same nucleosides and nelfinavir (NFV),
subjects on NFV were switched to atazanavir while those original-
ly assigned to atazanavir continued on this agent. To participate in
this study continuation phase, subjects had to have a viral load
les  than 10,000 copies/mL after 48 weeks on their originally
assigned regimen. Overall, the rates of maximal viral suppression
were not as impressive as in some recent studies. Approximately
40% to 50% of subjects initially randomized to atazanavir had viral
loads below 50 copies/mL after a year of treatment - no different
from NFV. However, among those with low
viral loads entering the study rollover, switch-
ing from NFV to atazanavir resulted a year
later in improved suppression of viral load
below 50 copies (a small jump from 44% to
49%) and increased CD4+ cell counts by
about 35 cells/mm3. Importantly, LDL choles-
terol, HDL cholesterol and triglycerides all
improved significantly after the switch. 
A catch for this convenient, lipid-friendly PI is
its own brand of toxicity. Hyperbilirubinemia
somewhat greater than that seen with indi-
navir (IDV) is very common in persons taking
this drug and frank jaundice can be expected
in 10% to 20% of patients. The elevated biliru-
bin is unconjugated (due to inhibition of biliru-
bin glucuronidation) and importantly does not
refl ct chemical hepatitis. 
Data regarding the development of resistance to atazanavir sug-
gest this agent will serve best as a first PI rather than as a salvage
agent because prior PI experience and resistance is associated
w th cross-resistance to atazanavir. Development of atazanavir
resistance in the ARV-naïve patient with its characteristic I50L
mutation actually increases susceptibility to a number of other PIs,
wh ch should appears to retain susceptibility to the other available
PIs. The combination of this data suggests that atazanavir will be
best used as part of an initial PI-containing regimen. It is also like-
ly that in patients receiving PIs who have dyslipidemias and risk
factors for cardiovascular disease but limited evidence of PI resis-
tance, substitution with atazanavir will become a popular alterna-
tive to lipid-lowering therapy.
Disclosures:
* Speaker's Bureau:  BMS, GSK, Merck, Roche, Gilead.
Grant/Research support:  BMS, GSK, Roche, Merck, Trimeris,
Boehringer-Ingleheim, Chiron, Pfizer, and Gilead. 
**Speaker's Bureau: GlaxoSmithKline, Gilead, Merck, Roche, and
Abbott. Grant support from Roche.
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New drugs... 
kinder and 
gentler PI 
therapy... 
and new classes 
of ARVs.
Despite the large impact HIV/AIDS is having
on correctional populations - and the
increasing attention this issue is receiving -
only one oral session and one poster at the
conference addressed HIV/AIDS among
inmates. 
Unsafe sex common among recently-
released HIV-positive inmates
David Alain Wohl, M.D., of the University of
North Carolina, presented results of a study1
of the post-release sexual practices of 86
HIV-infected state prison inmates. Wohl con-
ducted the study to better understand the
extent to which HIV-infected prison
releasees contribute to the spread of HIV in
communities to which they return.
"We noticed that there are many communi-
ties within the US in which the HIV infection
rates and the incarceration rates are high,"
Wohl told conference participants. "And we
were wondering if this is more than just a
coincidence."
The study found that more than half of the
HIV-infected inmates (51%) reported that
they had sex soon after they are released
from prison (the mean time was six days),
and about one third of these individuals
(26%) reported that they had unprotected
sex with their main sex partner, on average
within nine days of being released.
Interviews were conducted during incarcera-
tion and within three months after release.
Average prison stays were about one or two
years.
More than half (58%) of the study partici-
pants were women, 87% were non-white,
and 81% were heterosexual. The study was
done in North Carolina, a state that does not
perform mandatory HIV testing upon entry or
exit from prison.
The data were "surprising," Wohl said.
Seventy-five percent said they had a "main"
sex partner and 78% of these individuals
reported having unprotected sex with that
person one year before they went to prison.
Of the 57% who reported having other sex
partners, the average number of partners
was eight. The majority of partners in both
categories were not known to have HIV
infection.
All of the study participants said they had
told their main sex partners that they were
HIV-positive, but only two-thirds had told
their other sex partners.
Thirty percent reported they believed it was
"very likely" or "somewhat likely" that they
would infect their main sex partner.
"In many communities, prisons facilitate the
transmission of HIV by disrupting the social
fabric and sexual network...and also by tak-
ing people out of the community, locking
them up, and then releasing them to the
community," Wohl said. "Our experience has
been that when people get out of prison,
there are two things they want to do, and
one of them is to get a 'Big Mac."'
*DISCLOSURES: Nothing to disclose.
FOOTNOTES:
1. HIV Transmission Risk Behaviors Among
HIV-Infected Individuals Released from
Prison. D A Wohl, L Shain, M Adamian, B L
Stephenson, R Strauss, C Golin, A Kaplan.
Oral Abstract 36. 10th CROI, February
10-14, 2003.
2. HIV-related Health Beliefs, Attitudes, and
Adherence of Inmates in a Directly
Observed Treatment Setting. B L
Stephenson, D Wohl, R D Hays, C E Golin,
H Liu, G Simpson, A H Kaplan, N Kiziah.
Poster 917. 10th CROI, February 10-14,
2003.
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CROI: Correctional Updates
Resources & Websites
10th CROI  Webcasts and Abstracts
http://www.retroconference.org/2003/
10 CROI Conference Reports
http://www.natap.org/
http://www.thebody.com/confs/retro2003/retro2003.html
http://www.medscape.com/viewprogram/2221
Clinical Guide on Palliative Care of HIV/AIDS Patients
New HHS guidelines for clinicians on providing palliative and sup-
portive services to patients living with HIV/AIDS. Copies of the
guide are available online at ht p://hab.hrsa.govr may be ordered
from the HRSA Information Center at 1-888-275-4772.
Gender and HIV/AIDS Web Portal
A new online resource addressing gender-specific knowledge and
information. Sponsored by the United Nations Development Fund
for Women, the site offers research, training materials, surveys,
advocacy tools, current news and opinion pieces by leading
experts, and women's stories from the field.
http://www.GenderandAIDS.org
The Body Pro: The HIV/AIDS Resource for Healthcare
Professionals
A new online resource for HIV/AIDS health care professionals.
News, treatment strategies, conference coverage, and "treatment
library." Free one-time registration required for some content and
services. http://www.thebodypro.com
Nursing Care of the HIV-Infected Inmate: A Monograph Series
Continuing nursing education credit available. Module 1, available
now: "HIV Pathogenesis." Module 2, available in March: "HIV
Medication Overview." From the Albany Medical Center and spon-
sored by Gilead Sciences, Inc. 
http://www.amc.edu/Patient/hiv/hiv_modules.htm
HIV Correctional Health Care Resources
Correctional health care resources including videoconference
series, videotapes, and correctional education abstracts.
http://www.amc.edu/Patient/hiv/hiv_correctional.htm
PDA-Formatted Guidelines Available
The U.S. Department of Health and Human Services has posted
guidelines that can be downloaded and viewed in Palm OS or
Pocket PC PDAs. Guidelines include Health Care Worker
Exposure, Tuberculosis, Opportunistic Infections, Adult &
Adolescent Antiretroviral Therapy, Safety and Toxicity of Individual
Antiretroviral Agents in Pregnancy, and Hydroxyurea. 
http://aidsinfo.nih.gov/mobile/
CDC Public Health Emergency and Preparedness Response
Info, training, and resources for preparing and responding to bioter-
rorism, including smallpox and anthrax.
http://www.bt.cdc.gov/training/index.asp
Inmate Health Beliefs and Adherence
A poster presentation2 by Stephenson, et
al examined health beliefs and adherence
in a group of 65 North Carolina state
inmates with HIV infection. Inmates
almost uniformly believed that the PIs are
worth taking and likely would prolong their
life. Three-quarters trusted that their
health care provider prescribed the best
HIV medications and offered high-quality
medical care. Finally, 68% preferred to
self medicate ("Keep On Person") rather
than receive Directly Observed Therapy
(DOT) due to inconvenience and stigma-
tization issues.
Improving the Management of
HIV Disease
March 28, 2003
New York, New York
Email: cme@iasusa.org
Visit: www.iasusa.org/cme/
15th National HIV/AIDS Update
Conference
Focusing on the Front Lines:
Practical Lessons in Prevention,
Treatment, and Care
March 30-April 2, 2003
Miami, Florida
Email: nauc@total.net
Visit: www.amfar.org/nauc
2003 ACHSA Multidisciplinary
Training Conference
Health Services and Security
Working Together in Harmony
Co-hosted by the CDC and HRSA
April 10-13, 2003
Baltimore, Maryland
Call: 877-918-1842
Email:  achsa@mindspring.com
Visit: www.corrections.com/achsa
Clinical Updates in Correctional
Health Care
NCCHC Spring Meeting
April 12-15, 2003
Anaheim, CA
Call: 773.880.1460
Visit: www.ncchc.org
9th Annual Jail Health
Conference
May 12-13, 2003
Wisconsin Dells, Wisconsin
Visit: http://www.uwec.edu/CE/
43rd Interscience Conference
on Antimicrobial Agents and
Chemotherapy (ICAAC)
September 14-17, 2003
Chicago, Illinois
Call: 202-737-3600
Email: icaac@asmusa.org
Visit: www.icaac.org/ICAAC.asp
The United States Conference
on AIDS
Sponsored by the National
Minority AIDS Council
September 18-21, 2003
New Orleans, Louisiana
Call: 202-483-6622
Visit: www.nmac.org
National Conference on
Correctional Health Care
October 4-8, 2003
Austin, Texas
Call: 773-880-1460
Visit: www.ncchc.org
Save the 
Dates
7
FDA Approves Fuzeon
The Food and Drug Administration (FDA) granted
accelerated approval of enfuviritide (Fuzeon) for
use in combination with other anti-HIV medications
to treat advanced HIV infection. Fuzeon, also
known as T-20, is the first product in a new class
of medications called fusion inhibitors to receive
marketing approval. Unlike existing drugs that
work inside the cell, Fuzeon blocks HIV from enter-
ing healthy immune cells. The drug was designed
for patients in advanced stages of the disease who
have shown resistance to other AIDS drugs, and is
indicated for the treatment of HIV-1 infection in
treatment-experienced patients with evidence of
HIV-1 replication despite ongoing antiretroviral
therapy. Fuzeon is administered twice-daily as a
subcutaneous injection. Local injection site reac-
tions were the most common side effects reported,
and approved labeling warns physicians to careful-
ly monitor patients for signs and symptoms of
pneumonia.
Developed with Trimeris Inc. and Roche
Pharmaceuticals, Fuzeon will be distributed by
Roche. Initial demand for Fuzeon is expected to
outstrip supply, and the companies are still working
on a distribution plan. The U.S. price has not yet
been finalized, but is expected to reach new
records for drug pricing based on the price set in
Europe at 52 euros a day, or more than
$20,000/year. Roche says the high cost (more than
double the cost of other HIV/AIDS drugs on the
market) is due to the complexity of the manufac-
turing process, which involves more than 100 pro-
duction steps. FDA News and Reuters, 3/14/03
Trizivir Trial Halted: Less Effective When
Taken Alone
The National Institutes of Health (NIH) halted a trial
of GlaxoSmithKline's Trizivir (abacavir
sulfate/lamivudine/zidovudine) after it proved less
effective than when used in combination with other
AIDS drugs. The study involved 1,147 treatment-
naïve patients and compared Trizivir alone with a
combination of Trizivir and Sustiva (efavirenz), and
a combination of Sustiva and Combivir (lamivu-
dine/zidovudine). The NIH decided to stop the
Trizivir-only arm of the trial after participants in that
arm experienced virologic failure sooner and more
often than patients in the other two arms of the
study. After an average of 32 weeks in the study,
167 participants out of 1,147 experienced virologic
failure; 21% of the patients taking Trizivir alone
experienced failure, compared with 10% in the
other two arms of the study. The trial comparing
the other combinations will continue. Wall Street
Journal and Reuters, 3/13/03
FDA Issues Alert About Counterfeit Procrit
The US Food and Drug Administration warned
about counterfeit versions of Procrit (erythropoi-
etin) that are ineffective and contaminated with
bacteria that could harm patients. Laboratory test-
ing discovered the three lots of the counterfeit
Procrit with the following lot numbers and expira-
tion dates: P007645, expiration 10-2004;
P004677, expiration 02-2004; and P004839, expi-
ration 02-2004. If a counterfeit version is found, it
should be quarantined and the FDA should be noti-
fied (1-800-835-4709). FDA News, 3/11/03
NEJM: Antiretroviral Drugs Have Lower Heart
Attack, Stroke Risk Than Previously Stated
Contrary to data presented at the 10th CROI (see
the results from the D: A: D study discussed in the
main article), antiretroviral drugs do not cause
"premature" heart attack or stroke in HIV-positive
patients, according to a study published in the Feb.
20 issue of the New England Journal of Medicine.
Samuel Bozzette et al. conducted a retrospective
study of almost 37,000 patients who received care
for HIV infection at Veterans Affairs facilities
nationwide between 1993 and 2001. "Use of newer
therapies for HIV was associated with a large ben-
efit in terms of mortality that was not diminished by
any increase in the rate of cardiovascular or cere-
brovascular events or related mortality," the
authors state. New England Journal of Medicine,
2/20/03
Boehringer Ingelheim Launches Phase III
Clinical Trials for Tipranavir
Boehringer Ingelheim (BI) launched Phase III
RESIST clinical trials to study the efficacy and
safety of tipranavir for use in combination therapy
for HIV infection. Tipranavir is the first non-peptidic
protease inhibitor (NPPI) in development for the
treatment of HIV infection. The RESIST trials will
evaluate triple-class-experienced patients in more
than 280 clinical trial sites worldwide.
PRNewswire, 2/6/03
Officials Urge Increased Use of HIV Rapid Test
CDC officials at the 10th Conference on
Retroviruses and Opportunistic Infections (CROI)
called for more widespread use of a rapid HIV test
approved by the FDA in November 2002. More
widespread use could help curb the spread of the
disease by identifying newly-infected people as
soon as possible in order to reduce their chance of
transmitting the virus to others. The rapid test also
can be very useful in the setting of post-exposure
management of health care workers when the
source's HIV status is not known. Officials recom-
mended that the new test, which can provide
results in 20 minutes, be part of routine health care
for those at risk of infection. 
Boston Globe, 2/11/03
Nearly 41% of South Africa's Prison
Population is HIV-Positive
A study released by the nongovernmental Institute
for Security Studies estimates that nearly 41% of
inmates in South Africa's "overburdened" prisons
are infected with HIV/AIDS. Since 1995, reported
cases of HIV/AIDS in South African prisons rose by
750%, and the number of natural deaths in prison
have surged by about 600 percent. Most of the
deaths are believed to be AIDS-related. According
to Reuters, the disease's progress is being has-
tened by severe overcrowding in the prisons.
Reuters, 2/18/03
Inside News
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through September 30, 2003. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. A recent study of HIV+ inmates' sexual behavior after release
from prison found that:
(a) 70% had sex with their main sex partner within nine days 
of being released from prison.
(b) 45% had other sex partners in addition to their main sex 
partner. 
(c) 26% had unprotected sex with their main sex partner after 
being released.
(d) None of the above
2. The same study of HIV+ inmates' sexual behavior after release
also found that:
(a) All of the study participants reported that they informed 
their main sex partner of their HIV+ status.
(b) Only two-thirds of the study participants stated that they 
told their other sex partners of their HIV+ status. 
(c) Thirty percent reported they believed it was "very likely" or 
"somewhat likely" that they would infect their main sex partner.
(d) All of the above.
3. Data presented about atazanavir during the 10th CROI show
that the agent is commonly associated with the following side
effects:
(a) Injection site-reaction
(b) Hyperbilirubinemia 
(c) Elevated serum creatinine levels 
(d) Increased triglycerides
4. Results from the 903 Study, which compared the efficacy and
safety of a treatment regimen of tenofovir, lamivudine and efavirenz
to a regimen of stavudine, lamivudine and efavirenz showed that:
(a) The stavudine arm was much more effective in decreasing 
HIV viral load than the tenofovir arm.
(b) The tenofovir arm was much more effective in decreasing 
HIV viral load than the stavudine arm.
(c) The stavudine and tenofovir arms were equally effective in 
decreasing HIV viral load, and patients on the stavudine arm 
experienced substantially less lipodystrophy and lower 
elevations in fasting cholesterol and triglyceride levels.
(d) The stavudine and tenofovir arms were equally effective in 
decreasing HIV viral load, and patients on the tenofovir arm 
experienced substantially less lipodystrophy and lower 
elevations in fasting cholesterol and triglyceride levels.
5. At the 10th CROI, the CDCP reported that the greatest increas-
es in new HIV infections are now occurring in:
(a) Injection drug users
(b) Men who have sex with men
(c) Heterosexuals
(d) Both men who have sex with men and heterosexuals
6.  Data presented at the 10th CROI demonstrated that:
(a) Tenofovir increases the serum levels of ddI.
(b) ddI increases the serum levels of tenofovir.
(c) Lopinavir-ritonavir increases the serum levels of phenytoin.
(d) Tenofovir increases the serum levels of efavirenz.
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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